

ASX ANNOUNCEMENT

13 November 2018

RESPIRI



FUTURE MILESTONES SET FOR THE LAUNCH OF WHEEZO

Respiri Limited (ASX:RSH) is pleased to announce the future milestones in the commercialisation of Wheezo, the asthma monitoring ecosystem families with children suffering with asthma are waiting for. Having worked diligently throughout the year to meet the stated milestones, we are now set on a clearly defined pathway as we see preparation underway for manufacture of the first batch of units by SRX Global here in Australia and perform the necessary steps to complete the technical file for regulatory submission.

The attached Shareholder Update to accompany this morning's conference call at 9.30am outlines these new milestones.

Last month, we featured a video update from Professor Bruce Thompson on the unmet need for better symptom monitoring and the potential of Respiri technology to be a game changer. Today we invite you to view the product development update featuring Two Bulls partner, Evan Davey and Grey Innovation director, Jefferson Harcourt.

Please click [here](#) to view the video.

We hope you can join us for this morning's conference call. In the interests of providing you with the most comprehensive information within the limited time frame, questions are invited in writing throughout the presentation in real time. Questions will be prioritised for response and we will follow up directly on those we may not have time to cover off within the time.

Conference Call today at 9.30am AEDT

Telephone: 1800 123 296

Conference ID: 2797829

[Live questions email: admin@respiri.co](mailto:admin@respiri.co)

--END--

Contact:

Mario Gattino

CEO & Director

+61 3 9653 9160



About Respi Limited

Respi's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respi's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respi Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.